Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

Summary

Abbisko Therapeutics and AstraZeneca announced a strategic collaboration to conduct clinical trials of Lumipodlin (ABSK043), a first-in-class oral PD-L1 inhibitor, in combination with TAGRISSO for NSCLC. The partnership advances the joint clinical development of the investigational drug candidate.